2024年12月25日 · SLC3A2 (Solute Carrier Family 3 Member 2) is a Protein Coding gene. Diseases associated with SLC3A2 include Lysinuric Protein Intolerance and Hepatitis C Virus. Among its related pathways are Transport of inorganic cations/anions and amino acids/oligopeptides and Proximal tubule transport.

SLC3A2 inhibits ferroptosis in laryngeal carcinoma via mTOR pathway. The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2. Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells.

2019年10月1日 · On the basis of our findings, we conclude that CD98hc plays a central role in AA and glucose cellular nutrition, redox homeostasis and nucleotide availability, all key for cell proliferation....

SLC3A2 (CD98hc) is a tumor-associated antigen that is highly expressed in a variety of hematological and solid tumors, and due to its important role in tumorigenesis, progression, and metastasis, SLC3A2 transmembrane proteins are currently being considered as potential targets for the development of new cancer drugs [197].

2018年1月1日 · SLC3A2 constitutes the ancillary protein of six human amino acid transporters (SLC7A5, SLC7A6, SLC7A7, SLC7A8, SLC7A10, and SLC7A11; Fotiadis et al. 2013); it also functions as a coreceptor of β-integrins, amplifying their downstream outside-in …

2021年12月28日 · In the present study, we characterized the role of SLC3A2 during the unfolded protein response (UPR), as one of the primary pathways activated during ER stress. First, we confirmed the induction of Slc3a2 mRNA expression following treatment with various ER stress inducers in rat cardiomyocytes (H9C2) and neural cells (PC12).

2024年6月10日 · We identified SLC3A2 as a potential Anaplastic Lymphoma Kinase (ALK) interacting partner in a BioID-proximity labeling screen in neuroblastoma (NB) cells.

2022年8月5日 · The effect of SLC3A2 on the proliferation and drug resistance of cancer cell lines was evaluated by DEPMAP. Results: Upregulated SLC3A2 may have an adverse effect on the survival of multiple cancers such as lower-grade glioma and acute myeloid leukemia.

We demonstrated that SLC3A2 was upregulated in OS cell lines as well as OS tissues. High expression of SLC3A2 was correlated with clinical stage and tumor size in OS. Reduced expression of SLC3A2 inhibited OS cell proliferation through G2/M phase arrest.

SLC3A2 is a chaperone for light chain subunits such as SLC7A5 and SLC7A11/xCT by regulating their recruitment to the plasma membrane (Figure 1). By regulation of amino acid transport, SLC3A2 and SLC7A5 play an important role in tumor growth and controlling oxidative stress.